{"id":"W3204626226","doi":"10.1016/j.euf.2021.07.018","title":"Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non–muscle-invasive bladder cancer: Pro","year":2021,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Astellas Pharma; UroGen Pharma; AbbVie; Sanofi; Merck; Bayer; AstraZeneca; Pfizer","keywords":"Medicine; Gemcitabine; Docetaxel; Bladder cancer; Oncology; Urology; Second-line therapy; Standard of care; Internal medicine; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003856167,0.0002890465,0.0007925145,0.0003025805,0.0002361025,0.0005452876,0.0002973438,0.0004124707,0.002709576],"category_scores_gemma":[0.0005114351,0.0001318061,0.0006657147,0.0002860258,0.0002449681,0.000648533,0.0002875244,0.001317325,0.0005479327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005083355,"about_ca_system_score_gemma":0.0006030509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007059551,"about_ca_topic_score_gemma":0.004635206,"domain_scores_codex":[0.9998214,0.0000618072,0.00001732617,0.00003920393,0.0000220977,0.00003834331],"domain_scores_gemma":[0.999778,0.00004004929,0.00004583917,0.0000227045,0.0000239169,0.00008940839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.02621903,0.002424176,0.01242372,0.001570971,0.0006581425,0.0003426142,0.00009722032,0.002540724,0.01174827,0.001052606,0.01024072,0.9306816],"study_design_scores_gemma":[0.0292075,0.1708279,0.3140891,0.003393589,0.004881309,0.009914268,0.0006405984,0.0191676,0.04193397,0.005418071,0.4002609,0.0002651392],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8129131,0.155079,0.004175271,0.006955256,0.001806753,0.0004969302,0.0009193594,0.0002789629,0.01737536],"genre_scores_gemma":[0.9681255,0.02162141,0.002405162,0.001768813,0.0004467456,0.0001244794,0.0008248625,0.00003076213,0.004652294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002709576,"threshold_uncertainty_score":0.009064436,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03189313507915331,"score_gpt":0.3081511934025167,"score_spread":0.2762580583233634,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}